Crude Oil Falls 1%; US Services PMI Declines In June
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Nasdaq Composite gaining over 50 points, while the S&P Global US services PMI fell to 53.1 in June, slightly above market expectations.
Sector Movements and Notable Stocks: Consumer discretionary shares rose by 1.6%, while health care stocks declined. Significant stock movements included Impact BioMedical's shares surging 386% due to a merger announcement, and Hims & Hers Health's shares dropping 28% after a collaboration termination.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 42.88 USD with a low forecast of 29.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
7 Hold
3 Sell
Hold
Current: 28.670
Low
29.00
Averages
42.88
High
85.00
Current: 28.670
Low
29.00
Averages
42.88
High
85.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
New Ad Highlights Health Disparities in America
- Ad Campaign: Hims & Hers launches a new ad titled 'Rich People Live Longer' during the Super Bowl, emphasizing that proactive, life-changing healthcare should be accessible to everyone, challenging the notion of health as a luxury good.
- Health Disparity: Research indicates that the top 1% of earners live, on average, 7 years longer than those in the bottom 50%, highlighting the stark divide in the U.S. healthcare system and prompting public discourse on health equity.
- Platform Benefits: Hims & Hers offers personalized healthcare services, including early cancer detection and metabolic health management, aimed at removing barriers to high-quality care and improving overall health outcomes.
- Social Responsibility: CEO Andrew Dudum emphasizes that as living costs rise, more individuals are forced to treat health as a luxury, and the company's mission is to ensure everyone has access to the healthcare they need.
Continue Reading
Netflix Considers All-Cash Bid for Warner Bros. Discovery
- Acquisition Dynamics: Netflix is reportedly considering an all-cash bid for Warner Bros. Discovery, although the board's resistance to Paramount's offer complicates negotiations, potentially impacting Netflix's market position.
- Market Reaction: Warner Bros. Discovery's spin-off, Versant, has a market cap of $4.8 billion post-IPO, with shares dropping from $45 to $33, indicating market concerns about its future value, which may influence Netflix's acquisition strategy.
- Financial Risks: Netflix's acquisition approach could involve up to $60 billion in debt, and while it generates $7-8 billion in free cash flow annually, high leverage may restrict future investment flexibility and affect shareholder confidence.
- Competitive Pressure: Amid intensifying competition in the streaming industry, Netflix faces threats from platforms like YouTube; if the acquisition fails, it could weaken its market share and growth potential.
Continue Reading